semaglutide approval FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease TrimRX | Semaglutide vs Tirzepatide:

Optum Rx stands ready to help organizations futureproof their strategies, manage rising demand and maintain benefit affordability while delivering highquality care.

25 By following a plant-forward dietary pattern during GLP-1 therapy, patients can achieve a caloric deficit while helping their bodies remain nourished and reducing the long-term health risks associated with obesity

The medication's weight loss efficacyaveraging 1015% body weight reduction over 52 weeksoutweighs initial tolerability for most patients when managed properly

Inflammatory Bowel Disease: Treatments for IBD Flares and Remission

In contrast, adults aged 45 to 54 make up just 16.1% of the obesity population, but comprise 24.3% of GLP-1 users